Cabaletta Bio Earnings Reports

Cabaletta Bio reported its Q3 2024 financial results, highlighting the ongoing clinical execution with 40 U.S. clinical sites actively recruiting patients for the RESET clinical trial program for CABA-201. The company is preparing to present clinical data from the RESET-Myositis™, RESET-SLE™ and RESET-SSc™ trials at ACR Convergence 2024. Cabaletta expects its cash, cash equivalents and short-term investments to fund its operating plan into the first half of 2026.

Cabaletta Bio reported its second quarter 2024 financial results, highlighting increased enrollment in clinical trials, expansion of clinical sites, and advancements in its manufacturing strategy through new agreements with Lonza and Cellares. The company's cash, cash equivalents, and short-term investments totaled $203.2 million as of June 30, 2024, which is expected to fund operations into the first half of 2026.

Cabaletta Bio reported first quarter 2024 financial results, highlighting the progress of CABA-201 clinical trials and advancements in optimizing patient experience, along with upcoming presentations of initial clinical data.

Cabaletta Bio reported its Q4 and full year 2023 financial results. The company's cash, cash equivalents, and short-term investments totaled $241.2 million as of December 31, 2023, which is expected to fund operations into the first half of 2026. The first patient has been dosed with CABA-201 in the RESET™ clinical trial program.

Cabaletta Bio reported its third quarter 2023 financial results, highlighting the expansion of its CABA-201 clinical development program and progress towards initial clinical data in lupus and myositis trials, while also noting that cash, cash equivalents, and short-term investments are expected to support operations into the fourth quarter of 2025.

Cabaletta Bio reported its Q2 2023 financial results, highlighting the FDA clearance for CABA-201 in myositis and Fast Track Designation in SLE and LN. The company strengthened its balance sheet by closing a $100M public offering, extending its cash runway into the fourth quarter of 2025.

Cabaletta Bio reported first quarter 2023 financial results, including research and development expenses of $12.4 million and general and administrative expenses of $4.5 million. As of March 31, 2023, the company had cash and cash equivalents of $93.8 million, expected to fund operations into the first quarter of 2025. The IND application for CABA-201 has been cleared and Fast Track Designation was granted by the FDA.

Cabaletta Bio reported its Q4 and full year 2022 financial results, highlighting the expected IND clearance for CABA-201 in the first half of 2023 and potential initial clinical data by the first half of 2024.

Cabaletta Bio reported its third-quarter financial results, highlighting the progress of its CARTA and CAART platform, including CABA-201, DSG3-CAART, and MuSK-CAART. The company plans to submit an IND application to the FDA for CABA-201 in the first half of 2023 and expects initial clinical data by the first half of 2024. Cabaletta had cash, cash equivalents and investments of $85.9 million as of September 30, 2022, which is expected to fund operations through the second quarter of 2024.

Cabaletta Bio reported its second quarter financial results, highlighting the advancement of the DesCAARTes™ trial and the anticipation of upcoming milestones. With sufficient cash to fund operations through Q1 2024, the company focuses on developing targeted cell therapies for autoimmune diseases.

Cabaletta Bio reported first quarter 2022 financial results, highlighting the progress of its DesCAARTes™ Phase 1 trial and the upcoming first-in-human trial of MuSK-CAART. The company's cash, cash equivalents, and investments totaled $109.2 million as of March 31, 2022, expected to fund operations through Q3 2023.

Cabaletta Bio reported its Q4 and full year 2021 financial results. The company's DesCAARTes trial is progressing, and the MuSK-CAART IND application was cleared with Fast Track Designation granted by the FDA. The company ended the year with $122.2 million in cash on hand.

Cabaletta Bio announced encouraging momentum in the DesCAARTes™ trial for DSG3-CAART, with dose-dependent increases in DSG3-CAART persistence observed. The company ended the quarter with $119.3 million in cash, extending the cash runway through at least Q1 2023.

Cabaletta Bio reported their Q2 2021 financial results. Key highlights include no clinically relevant adverse events observed in the first patient cohort of the DesCAARTes™ clinical trial for DSG3-CAART and remaining on track to submit an IND to the FDA for MuSK-CAART.

Cabaletta Bio reported the acute safety data from the first cohort in the DesCAARTes™ trial with no dose limiting toxicities or clinically relevant adverse events. They also announced PLA2R-CAART as a new development program and are planning to submit an IND application for MuSK-CAART in the second half of 2021.

Cabaletta Bio announced its fourth quarter and full year 2020 financial results, highlighting the dosing of the first patient in its Phase 1 clinical trial for DSG3-CAART and the advancement of its pipeline.

Cabaletta Bio reported its Q3 2020 financial results, highlighting the ongoing patient enrollment for the DSG3-CAART program and the anticipation of acute safety data in the first half of 2021. The company's cash and investments are expected to fund operations through at least Q3 2022.

Cabaletta Bio reported R&D expenses of $5.3 million and G&A expenses of $2.9 million for the three months ended June 30, 2020. As of June 30, 2020, cash, cash equivalents and investments totaled $123.2 million.

Cabaletta Bio reported first quarter 2020 financial results, with research and development expenses at $4.6 million and general and administrative expenses at $3.3 million. Cash and cash equivalents totaled $131.0 million as of March 31, 2020.

Cabaletta Bio reported its Q4 and full-year 2019 financial results, highlighting the FDA clearance of the IND for their lead product candidate, DSG3-CAART, and ending the year with approximately $136 million in cash and cash equivalents.